Valuation ratios measure the quantity of an asset or flaw (e.g., earnings) associated with ownership of a specified claim (e.g., a share of ownership of the enterprise).
Current Valuation Ratios
| IQVIA Holdings Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | Pharmaceuticals, Biotechnology & Life Sciences | Health Care | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||||||||||||||
| Current share price (P) | $180.01 | |||||||||||||||||
| No. shares of common stock outstanding | 182,500,000 | |||||||||||||||||
| Growth rate (g) | 8.50% | |||||||||||||||||
| Earnings per share (EPS) | $5.98 | |||||||||||||||||
| Next year expected EPS | $6.49 | |||||||||||||||||
| Operating profit per share | $9.86 | |||||||||||||||||
| Sales per share | $78.96 | |||||||||||||||||
| Book value per share (BVPS) | $31.59 | |||||||||||||||||
| Valuation Ratios (Price Multiples) | ||||||||||||||||||
| Price to earnings (P/E) | 30.11 | 110.53 | 29.07 | 18.20 | 43.67 | 53.98 | 21.99 | 24.38 | 20.11 | 21.03 | 18.01 | 37.23 | 33.74 | 32.43 | 29.79 | |||
| Price to next year expected earnings | 27.75 | 599.18 | 21.56 | 16.58 | 40.27 | 41.42 | 30.24 | 21.47 | — | 22.74 | 15.31 | 32.84 | 28.75 | 28.01 | 26.06 | |||
| Price-earnings-growth (PEG) | 3.54 | — | 0.83 | 1.86 | 5.17 | 1.78 | — | 1.79 | — | — | 1.02 | 2.79 | 1.94 | 2.06 | 2.08 | |||
| Price to operating profit (P/OP) | 18.26 | 30.99 | 24.69 | 12.84 | 33.65 | 42.36 | 18.67 | 25.85 | 17.30 | 11.47 | 22.68 | 32.22 | 31.96 | 25.55 | 23.27 | |||
| Price to sales (P/S) | 2.28 | 7.64 | 6.38 | 2.66 | 6.42 | 17.09 | 6.47 | 6.94 | 5.65 | 2.61 | 5.66 | 5.60 | 11.11 | 7.31 | 4.36 | |||
| Price to book value (P/BV) | 5.70 | — | 25.89 | 6.95 | 3.00 | 41.98 | 8.24 | 8.02 | 6.98 | 1.89 | 2.60 | 4.67 | 7.15 | 9.07 | 7.39 | |||
Based on: 10-K (reporting date: 2022-12-31).
If the company price multiple is lower then the price multiple of benchmark then company stock is relatively undervalued.
Otherwise, if the company price multiple is higher then the price multiple of benchmark then company stock is relatively overvalued.
Historical Valuation Ratios (Summary)
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
The valuation multiples for the period between 2018 and 2022 exhibit a notable transition from extremely high earnings multiples toward more compressed valuation levels, contrasted by a steady increase in book value premiums.
- Earnings and Operating Profit Multiples
- A significant contraction is observed in the Price to Earnings (P/E) ratio, which peaked at 166.58 in 2019 before declining sharply to 38.65 by 2022. Similarly, the Price to Operating Profit (P/OP) ratio increased from 37.73 in 2018 to a peak of 50.41 in 2020, subsequently falling to 23.44 in 2022. This downward trajectory in both ratios suggests either a substantial increase in bottom-line profitability or a market re-rating of the valuation premium applied to earnings.
- Sales Valuation
- The Price to Sales (P/S) ratio remained relatively stable throughout the five-year period. After a modest rise from 2.69 in 2018 to a peak of 3.24 in 2020, the ratio moderated to 2.93 by 2022, indicating a consistent relationship between market capitalization and revenue generation.
- Book Value Premium
- In contrast to the earnings-based metrics, the Price to Book Value (P/BV) ratio demonstrated a consistent upward trend. The ratio grew steadily from 4.16 in 2018 to 7.31 in 2022, reflecting an increasing market valuation relative to the company's net asset value over the analyzed timeframe.
AI Ask an analyst for more
Price to Earnings (P/E)
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | ||
|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 185,722,621 | 190,485,264 | 191,281,286 | 192,339,093 | 197,599,861 | |
| Selected Financial Data (US$) | ||||||
| Net income attributable to IQVIA Holdings Inc. (in millions) | 1,091) | 966) | 279) | 191) | 259) | |
| Earnings per share (EPS)2 | 5.87 | 5.07 | 1.46 | 0.99 | 1.31 | |
| Share price1, 3 | 227.03 | 232.18 | 192.66 | 165.42 | 141.49 | |
| Valuation Ratio | ||||||
| P/E ratio4 | 38.65 | 45.78 | 132.09 | 166.58 | 107.95 | |
| Benchmarks | ||||||
| P/E Ratio, Competitors5 | ||||||
| AbbVie Inc. | 22.62 | 22.07 | — | — | — | |
| Amgen Inc. | 19.56 | 21.05 | — | — | — | |
| Bristol-Myers Squibb Co. | 23.97 | 20.92 | — | — | — | |
| Danaher Corp. | 25.65 | 29.94 | — | — | — | |
| Eli Lilly & Co. | 50.08 | 40.66 | — | — | — | |
| Gilead Sciences Inc. | 22.68 | 12.36 | — | — | — | |
| Johnson & Johnson | 22.97 | 20.93 | — | — | — | |
| Merck & Co. Inc. | 19.21 | 14.78 | — | — | — | |
| Pfizer Inc. | 7.58 | 11.76 | — | — | — | |
| Regeneron Pharmaceuticals Inc. | 19.68 | 8.37 | — | — | — | |
| Thermo Fisher Scientific Inc. | 30.55 | 27.35 | — | — | — | |
| Vertex Pharmaceuticals Inc. | 23.02 | 26.55 | — | — | — | |
| P/E Ratio, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 20.23 | 19.27 | — | — | — | |
| P/E Ratio, Industry | ||||||
| Health Care | 21.22 | 21.55 | — | — | — | |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 Data adjusted for splits and stock dividends.
2 2022 Calculation
EPS = Net income attributable to IQVIA Holdings Inc. ÷ No. shares of common stock outstanding
= 1,091,000,000 ÷ 185,722,621 = 5.87
3 Closing price as at the filing date of IQVIA Holdings Inc. Annual Report.
4 2022 Calculation
P/E ratio = Share price ÷ EPS
= 227.03 ÷ 5.87 = 38.65
5 Click competitor name to see calculations.
Between 2018 and 2022, the share price exhibited a general upward trajectory, rising from 141.49 to a peak of 232.18 in 2021 before a slight correction to 227.03 in 2022. During the same period, earnings per share (EPS) demonstrated significant acceleration, particularly after 2020, moving from 1.31 in 2018 to 5.87 by the end of 2022.
- Price-to-Earnings (P/E) Ratio Trend
- The P/E ratio experienced substantial volatility, peaking at 166.58 in 2019 before entering a consistent decline to 38.65 by 2022. This compression indicates a shift in valuation dynamics where share price appreciation was eventually outpaced by a rapid increase in realized earnings.
- Earnings Growth and Valuation Compression
- A marked divergence is observed between 2020 and 2021, where EPS increased from 1.46 to 5.07, contributing to a sharp decrease in the P/E ratio from 132.09 to 45.78. This suggests that the exceptionally high multiples observed between 2018 and 2020 were largely driven by growth expectations, while the subsequent years reflect a valuation more closely aligned with fundamental earning performance.
- Share Price and EPS Correlation
- While the share price increased by approximately 60% over the five-year period, EPS grew by approximately 347%. The resulting downward trend in the P/E ratio confirms that the expansion of the company's earnings capacity was the primary driver in normalizing the valuation multiple.
AI Ask an analyst for more
Price to Operating Profit (P/OP)
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | ||
|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 185,722,621 | 190,485,264 | 191,281,286 | 192,339,093 | 197,599,861 | |
| Selected Financial Data (US$) | ||||||
| Income from operations (in millions) | 1,799) | 1,393) | 731) | 777) | 741) | |
| Operating profit per share2 | 9.69 | 7.31 | 3.82 | 4.04 | 3.75 | |
| Share price1, 3 | 227.03 | 232.18 | 192.66 | 165.42 | 141.49 | |
| Valuation Ratio | ||||||
| P/OP ratio4 | 23.44 | 31.75 | 50.41 | 40.95 | 37.73 | |
| Benchmarks | ||||||
| P/OP Ratio, Competitors5 | ||||||
| AbbVie Inc. | 14.78 | 14.21 | — | — | — | |
| Amgen Inc. | 13.40 | 16.24 | — | — | — | |
| Bristol-Myers Squibb Co. | 18.29 | 19.84 | — | — | — | |
| Danaher Corp. | 20.97 | 25.14 | — | — | — | |
| Eli Lilly & Co. | 43.88 | 35.70 | — | — | — | |
| Gilead Sciences Inc. | 14.21 | 7.76 | — | — | — | |
| Johnson & Johnson | 17.62 | 18.68 | — | — | — | |
| Merck & Co. Inc. | 15.55 | 15.39 | — | — | — | |
| Pfizer Inc. | 6.64 | 12.74 | — | — | — | |
| Regeneron Pharmaceuticals Inc. | 18.01 | 7.55 | — | — | — | |
| Thermo Fisher Scientific Inc. | 25.30 | 21.07 | — | — | — | |
| Vertex Pharmaceuticals Inc. | 17.75 | 22.35 | — | — | — | |
| P/OP Ratio, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 15.94 | 16.68 | — | — | — | |
| P/OP Ratio, Industry | ||||||
| Health Care | 16.58 | 18.20 | — | — | — | |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 Data adjusted for splits and stock dividends.
2 2022 Calculation
Operating profit per share = Income from operations ÷ No. shares of common stock outstanding
= 1,799,000,000 ÷ 185,722,621 = 9.69
3 Closing price as at the filing date of IQVIA Holdings Inc. Annual Report.
4 2022 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= 227.03 ÷ 9.69 = 23.44
5 Click competitor name to see calculations.
An analysis of the valuation multiples from 2018 to 2022 reveals a significant shift in the relationship between market pricing and operational profitability.
- Share Price Trend
- The share price experienced a consistent upward trajectory from 2018 through 2021, increasing from 141.49 to a peak of 232.18. A slight correction occurred in 2022, with the price settling at 227.03.
- Operating Profit per Share Growth
- Operational performance remained relatively flat between 2018 and 2020, with operating profit per share fluctuating within a narrow range of 3.75 to 4.04. A sharp inflection point occurred in 2021, where profit per share jumped to 7.31, followed by further growth to 9.69 in 2022, representing a substantial increase in earnings power over the five-year period.
- Price to Operating Profit (P/OP) Dynamics
- The P/OP ratio exhibited two distinct phases. From 2018 to 2020, a valuation expansion occurred, with the ratio rising from 37.73 to a peak of 50.41, suggesting that share price growth was outpacing the growth of operating profits. Conversely, from 2021 to 2022, a period of valuation compression was observed, as the ratio declined sharply to 31.75 and then to 23.44. This contraction indicates that the rapid growth in operating profits significantly exceeded the growth in share price, resulting in a lower multiple.
The overall trend indicates a transition from a valuation driven by market expectation and price appreciation to one supported by strong fundamental growth in operating profitability. By 2022, the stock traded at its lowest P/OP multiple of the period despite the share price remaining near its historical high.
AI Ask an analyst for more
Price to Sales (P/S)
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | ||
|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 185,722,621 | 190,485,264 | 191,281,286 | 192,339,093 | 197,599,861 | |
| Selected Financial Data (US$) | ||||||
| Revenues (in millions) | 14,410) | 13,874) | 11,359) | 11,088) | 10,412) | |
| Sales per share2 | 77.59 | 72.84 | 59.38 | 57.65 | 52.69 | |
| Share price1, 3 | 227.03 | 232.18 | 192.66 | 165.42 | 141.49 | |
| Valuation Ratio | ||||||
| P/S ratio4 | 2.93 | 3.19 | 3.24 | 2.87 | 2.69 | |
| Benchmarks | ||||||
| P/S Ratio, Competitors5 | ||||||
| AbbVie Inc. | 4.61 | 4.53 | — | — | — | |
| Amgen Inc. | 5.17 | 5.10 | — | — | — | |
| Bristol-Myers Squibb Co. | 3.29 | 3.16 | — | — | — | |
| Danaher Corp. | 5.79 | 6.37 | — | — | — | |
| Eli Lilly & Co. | 10.96 | 8.01 | — | — | — | |
| Gilead Sciences Inc. | 3.86 | 2.85 | — | — | — | |
| Johnson & Johnson | 4.34 | 4.66 | — | — | — | |
| Merck & Co. Inc. | 4.71 | 3.96 | — | — | — | |
| Pfizer Inc. | 2.35 | 3.15 | — | — | — | |
| Regeneron Pharmaceuticals Inc. | 7.01 | 4.20 | — | — | — | |
| Thermo Fisher Scientific Inc. | 4.73 | 5.39 | — | — | — | |
| Vertex Pharmaceuticals Inc. | 8.56 | 8.21 | — | — | — | |
| P/S Ratio, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 4.56 | 4.50 | — | — | — | |
| P/S Ratio, Industry | ||||||
| Health Care | 3.11 | 3.28 | — | — | — | |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 Data adjusted for splits and stock dividends.
2 2022 Calculation
Sales per share = Revenues ÷ No. shares of common stock outstanding
= 14,410,000,000 ÷ 185,722,621 = 77.59
3 Closing price as at the filing date of IQVIA Holdings Inc. Annual Report.
4 2022 Calculation
P/S ratio = Share price ÷ Sales per share
= 227.03 ÷ 77.59 = 2.93
5 Click competitor name to see calculations.
The analysis of the common stock valuation ratios reveals a period of expansion in the price-to-sales multiple followed by a moderate contraction. While both the absolute share price and the sales per share demonstrated general growth over the five-year period, the valuation multiple experienced a non-linear trajectory, peaking in 2020.
- Share Price Performance
- The share price exhibited a strong upward trend for the majority of the period, rising from 141.49 US$ in 2018 to a peak of 232.18 US$ in 2021, before experiencing a slight correction to 227.03 US$ by the end of 2022.
- Revenue Efficiency per Share
- Sales per share grew monotonically throughout the observed duration, increasing from 52.69 US$ in 2018 to 77.59 US$ in 2022. This consistent year-over-year growth indicates a steady increase in revenue generation on a per-share basis.
- Price-to-Sales (P/S) Ratio Dynamics
- The P/S ratio rose from 2.69 in 2018 to a peak of 3.24 in 2020, reflecting an expansion in the valuation premium investors were willing to pay relative to revenue. Following 2020, a downward trend is observed, with the ratio compressing to 3.19 in 2021 and further to 2.93 in 2022. This decline in the multiple occurred despite continued growth in sales per share, suggesting a normalization of the valuation multiple toward 2022 levels.
AI Ask an analyst for more
Price to Book Value (P/BV)
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | ||
|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 185,722,621 | 190,485,264 | 191,281,286 | 192,339,093 | 197,599,861 | |
| Selected Financial Data (US$) | ||||||
| Equity attributable to IQVIA Holdings Inc.’s stockholders (in millions) | 5,765) | 6,042) | 6,001) | 6,003) | 6,714) | |
| Book value per share (BVPS)2 | 31.04 | 31.72 | 31.37 | 31.21 | 33.98 | |
| Share price1, 3 | 227.03 | 232.18 | 192.66 | 165.42 | 141.49 | |
| Valuation Ratio | ||||||
| P/BV ratio4 | 7.31 | 7.32 | 6.14 | 5.30 | 4.16 | |
| Benchmarks | ||||||
| P/BV Ratio, Competitors5 | ||||||
| AbbVie Inc. | 15.52 | 16.53 | — | — | — | |
| Amgen Inc. | 35.01 | 18.51 | — | — | — | |
| Bristol-Myers Squibb Co. | 4.88 | 4.07 | — | — | — | |
| Danaher Corp. | 3.64 | 4.16 | — | — | — | |
| Eli Lilly & Co. | 29.36 | 25.28 | — | — | — | |
| Gilead Sciences Inc. | 4.90 | 3.65 | — | — | — | |
| Johnson & Johnson | 5.37 | 5.90 | — | — | — | |
| Merck & Co. Inc. | 6.07 | 5.05 | — | — | — | |
| Pfizer Inc. | 2.48 | 3.35 | — | — | — | |
| Regeneron Pharmaceuticals Inc. | 3.77 | 3.60 | — | — | — | |
| Thermo Fisher Scientific Inc. | 4.83 | 5.18 | — | — | — | |
| Vertex Pharmaceuticals Inc. | 5.50 | 6.16 | — | — | — | |
| P/BV Ratio, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 5.66 | 5.72 | — | — | — | |
| P/BV Ratio, Industry | ||||||
| Health Care | 5.26 | 5.48 | — | — | — | |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 Data adjusted for splits and stock dividends.
2 2022 Calculation
BVPS = Equity attributable to IQVIA Holdings Inc.’s stockholders ÷ No. shares of common stock outstanding
= 5,765,000,000 ÷ 185,722,621 = 31.04
3 Closing price as at the filing date of IQVIA Holdings Inc. Annual Report.
4 2022 Calculation
P/BV ratio = Share price ÷ BVPS
= 227.03 ÷ 31.04 = 7.31
5 Click competitor name to see calculations.
Between 2018 and 2022, the valuation of the equity relative to its book value experienced a consistent and significant expansion. The price-to-book value (P/BV) ratio grew from 4.16 in 2018 to 7.31 by the end of 2022, reflecting a marked increase in the market premium attributed to the company's net assets.
- Share Price Trends
- The share price exhibited a strong upward trajectory for the majority of the period, rising from US$ 141.49 in 2018 to a peak of US$ 232.18 in 2021, before experiencing a marginal decline to US$ 227.03 in 2022.
- Book Value Per Share (BVPS) Stability
- In contrast to the share price, the book value per share remained relatively stagnant. After an initial decrease from US$ 33.98 in 2018 to US$ 31.21 in 2019, the BVPS fluctuated within a narrow range, ending the period at US$ 31.04 in 2022.
- P/BV Ratio Interpretation
- The steady increase in the P/BV ratio—from 4.16 in 2018 to 7.31 in 2022—is primarily driven by the divergence between the rising market price and the flat book value. This pattern indicates that the market has placed an increasing valuation on the company's intangible assets, intellectual property, or future growth prospects rather than its tangible accounting value.
AI Ask an analyst for more